Pfizer Files Q1 2025 10-Q Report
Ticker: PFE · Form: 10-Q · Filed: 2025-05-05T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, financials, pharmaceuticals
TL;DR
Pfizer's Q1 2025 10-Q is in: financials look steady, company continues pharma ops.
AI Summary
Pfizer Inc. filed its 10-Q for the period ending March 30, 2025. The filing details financial performance and operational updates for the first quarter of 2025. Key financial data and business segments are presented, reflecting the company's ongoing activities in the pharmaceutical sector.
Why It Matters
This report provides investors and analysts with the latest financial health and operational performance of Pfizer, a major pharmaceutical company, influencing investment decisions and market perception.
Risk Assessment
Risk Level: low — This is a routine quarterly financial filing with no immediate red flags or significant negative events indicated.
Key Numbers
- 2025-03-30 — Reporting Period End Date (Indicates the end of the financial quarter being reported.)
- 2025-01-01 — Reporting Period Start Date (Indicates the start of the financial quarter being reported.)
- 2024-12-31 — Previous Year End Date (Provides a comparison point to the end of the prior fiscal year.)
Key Players & Entities
- Pfizer Inc. (company) — Filer of the 10-Q report
- 20250330 (date) — End of the reporting period
- 20250505 (date) — Filing date of the report
- 2834 (dollar_amount) — Standard Industrial Classification code for Pharmaceutical Preparations
FAQ
What is the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing is March 30, 2025.
When was this 10-Q filed with the SEC?
This 10-Q was filed on May 5, 2025.
What is Pfizer Inc.'s Standard Industrial Classification code?
Pfizer Inc.'s Standard Industrial Classification code is 2834, which corresponds to Pharmaceutical Preparations.
What is the fiscal year end for Pfizer Inc.?
Pfizer Inc.'s fiscal year ends on December 31.
What is the business address listed for Pfizer Inc.?
The business address listed for Pfizer Inc. is 66 Hudson Boulevard East, New York, NY 10001-2192.
From the Filing
0000078003-25-000114.txt : 20250505 0000078003-25-000114.hdr.sgml : 20250505 20250505160034 ACCESSION NUMBER: 0000078003-25-000114 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 96 CONFORMED PERIOD OF REPORT: 20250330 FILED AS OF DATE: 20250505 DATE AS OF CHANGE: 20250505 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PFIZER INC CENTRAL INDEX KEY: 0000078003 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 135315170 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-03619 FILM NUMBER: 25912745 BUSINESS ADDRESS: STREET 1: 66 HUDSON BOULEVARD EAST CITY: NEW YORK STATE: NY ZIP: 10001-2192 BUSINESS PHONE: 2127332323 MAIL ADDRESS: STREET 1: 66 HUDSON BOULEVARD EAST CITY: NEW YORK STATE: NY ZIP: 10001-2192 FORMER COMPANY: FORMER CONFORMED NAME: PFIZER CHARLES & CO INC DATE OF NAME CHANGE: 19710908 10-Q 1 pfe-20250330.htm 10-Q pfe-20250330 0000078003 12/31 2025 Q1 false P1Y P3Y P5Y P7Y xbrli:shares iso4217:USD iso4217:USD xbrli:shares pfe:segment xbrli:pure pfe:company pfe:patent pfe:complaint pfe:treatment_course 0000078003 2025-01-01 2025-03-30 0000078003 us-gaap:CommonStockMember 2025-01-01 2025-03-30 0000078003 pfe:NotesDue20271.000Member 2025-01-01 2025-03-30 0000078003 2025-04-30 0000078003 us-gaap:ProductMember 2025-01-01 2025-03-30 0000078003 us-gaap:ProductMember 2024-01-01 2024-03-31 0000078003 2024-01-01 2024-03-31 0000078003 us-gaap:RoyaltyMember 2025-01-01 2025-03-30 0000078003 us-gaap:RoyaltyMember 2024-01-01 2024-03-31 0000078003 2025-03-30 0000078003 2024-12-31 0000078003 us-gaap:CommonStockMember 2024-12-31 0000078003 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0000078003 us-gaap:TreasuryStockCommonMember 2024-12-31 0000078003 us-gaap:RetainedEarningsMember 2024-12-31 0000078003 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0000078003 us-gaap:ParentMember 2024-12-31 0000078003 us-gaap:NoncontrollingInterestMember 2024-12-31 0000078003 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-30 0000078003 us-gaap:ParentMember 2025-01-01 2025-03-30 0000078003 us-gaap:NoncontrollingInterestMember 2025-01-01 2025-03-30 0000078003 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-03-30 0000078003 us-gaap:CommonStockMember 2025-01-01 2025-03-30 0000078003 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-30 0000078003 us-gaap:TreasuryStockCommonMember 2025-01-01 2025-03-30 0000078003 us-gaap:CommonStockMember 2025-03-30 0000078003 us-gaap:AdditionalPaidInCapitalMember 2025-03-30 0000078003 us-gaap:TreasuryStockCommonMember 2025-03-30 0000078003 us-gaap:RetainedEarningsMember 2025-03-30 0000078003 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-30 0000078003 us-gaap:ParentMember 2025-03-30 0000078003 us-gaap:NoncontrollingInterestMember 2025-03-30 0000078003 us-gaap:CommonStockMember 2023-12-31 0000078003 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000078003 us-gaap:TreasuryStockCommonMember 2023-12-31 0000078003 us-gaap:RetainedEarningsMember 2023-12-31 0000078003 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000078003 us-gaap:ParentMember 2023-12-31 0000078003 us-gaap:NoncontrollingInterestMember 2023-12-31 0000078003 2023-12-31 0000078003 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0000078003 us-gaap:ParentMember 2024-01-01 2024-03-31 0000078003 us-gaap:NoncontrollingInterestMember 2024-01-01 2024-03-31 0000078003 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0000078003 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0000078003 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0000078003 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-03-31 0000078003 us-gaap:CommonStockMember 2024-03-31 0000078003 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0000078003 us-gaap:TreasuryStockCommonMember 2024-03-31 0000078003 us-gaap:RetainedEarningsMember 2024-03-31 0000078003 us-gaap:A